ESSA Pharma Inc (TSX-V: EPI)(NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported yesterday its financial results for the year ended 30 September 2018.
The company reported a net loss of USD11.6m for the year ended 30 September 2018, compared to a net loss of USD4.5m in the year-ago period.
The firm posted research and development expenditures for the year ended 30 September 2018 at USD4.9m net of grants compared to USD5.7m net of grants for the year ended 30 September 2017.
Cash on hand at 30 September 2018, was USD14.8m, with working capital of USD12.3m, reflecting the aggregate gross proceeds of the completed January 2018 financing, which totalled USD26m.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886